Filing Flows › Vertex Pharmaceuticals (VRTX) › R&D spending
Vertex Pharmaceuticals (VRTX) R&D spending by quarter
Vertex Pharmaceuticals' R&D spending was $1.3B in Q3 2026 (third quarter 2026), +33% from Q2 2026. Over the last 7 quarters it ranged from $962M (Q1 2026) to $1.3B (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.3B | +33% | +35% |
| Q2 2026 | $994M | +3% | +2% |
| Q1 2026 | $962M | -1% | -2% |
| Q4 2025 | $974M | -0.4% | — |
| Q3 2025 | $978M | -0.1% | — |
| Q2 2025 | $978M | -0.1% | — |
| Q1 2025 | $980M | — | — |
Q3 2026 at a glance
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vertex Pharmaceuticals' R&D spending?
Vertex Pharmaceuticals' R&D spending was $1.3B in Q3 2026 (third quarter 2026), +33% from Q2 2026.
How has Vertex Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $962M (Q1 2026) to $1.3B (Q3 2026).
Q3 2026 results → · How Vertex Pharmaceuticals makes money →